| 标题 |
 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: Systematic review and economic evaluation |
| 网址 | |
| DOI | |
| 其它 | STEVENSON M, ARCHER R, TOSH J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: Systematic review and economic evaluation[J]. Health Technol Assess, 2016, 20(35): 1-610. |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时，文件已从服务器自动删除，无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
璐璐
invisight
DW
v0id
林狗
aaaa
xing_xing
牧青
极限001
123
wangyumumu
pluto
渡人舟
aajhajkahna
wch666
谢雷XIELei
zd
学术文献互助
佚名
嘻嘻哈哈
皖公网安备34019202002308
